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Background: Edoxaban is an oral, direct, factor Xa inhibitor approved in Japan for thromboembolic prophylaxis
after lower-limb orthopedic surgery (LLOS), but contraindicated in patients with severe renal impairment
(SRI; creatinine clearance [CLCR] ≥15 to <30 mL/min).
Methods: This open-label study compared the safety of edoxaban 15 mg once daily in Japanese patients with
SRI to that of edoxaban 30 mg in patients with mild renal impairment (MiRI; CLCR ≥50 to ≤80 mL/min; N = 30)
undergoing LLOS. Patients with CLCR ≥20 to <30 mL/min were randomized to receive edoxaban 15 mg (N = 22)
or subcutaneous fondaparinux 1.5 mg once daily (N = 21). All patients with CLCR ≥15 to <20 mL/min received
edoxaban 15 mg (N = 7). Treatment was administered for 11 to 14 days.
Results: Major or clinically relevant non-major bleeding occurred in 6.7%, 3.4%, and 5.0% of patients in
the MiRI edoxaban 30-mg, SRI edoxaban 15-mg, and SRI fondaparinux groups, respectively; there were
no major bleeding events. No thromboembolic events occurred. At all time points assessed, edoxaban
plasma concentrations and changes in coagulation biomarkers were similar between the SRI and MiRI
groups.
Conclusions: These results suggest edoxaban 15 mg once daily is well tolerated in Japanese patients
with SRI undergoing LLOS.
Trial registration: Clinicaltrials.gov Identifier: NCT01857583.
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Lower-limb orthopedic surgery (LLOS), including total
knee arthroplasty (TKA), total hip arthroplasty (THA),
and hip fracture surgery (HFS), is considered a high risk
factor for the development of venous thromboembolism
(VTE). As such, current guidelines for the prevention of
VTE, including those from the American College of
Chest Physicians and the Japanese Circulation Society,
recommend anticoagulation therapy for VTE preven-
tion in patients undergoing LLOS [1-4]. Anticoagulants* Correspondence: fuji-th@umin.ac.jp
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undergoing LLOS include the subcutaneous low-molecular
weight heparin (LMWH) enoxaparin; subcutaneous
fondaparinux; orally administered warfarin; and the
oral, direct factor Xa inhibitor edoxaban [5-8].
In Japan, the majority of patients undergoing LLOS
are ≥70 years of age [9]; older individuals are at in-
creased risk for developing renal impairment [10]. Cur-
rently, there are limited therapeutic options available
in Japan for the prevention of VTE following LLOS in
patients with severe renal impairment (SRI; creatinine
clearance [CLCR] ≥15 to <30 mL/min). Enoxaparin is
contraindicated in patients with CLCR <30 mL/min [5]
and fondaparinux is not approved for use in patientsis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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dicated in patients with serious renal impairment [8].
Edoxaban is a novel, oral, highly specific and direct in-
hibitor of factor Xa, which is a key serine endopeptidase
of the coagulation cascade [11]. Edoxaban has predict-
able pharmacokinetics (PK), a rapid onset of action with
approximately 62% oral bioavailability [12], and low
intrasubject variability [13]. Approximately 50% of the
absorbed edoxaban dose is renally eliminated [12]. Cur-
rently, edoxaban 30 mg once daily is approved in Japan
for the prevention of VTE in patients undergoing LLOS
but is contraindicated in patients with SRI [7]. A popula-
tion pharmacometric analysis of pooled data from edox-
aban phase 1 and 2 clinical trials, including a phase 2b
study in patients undergoing THA [14], revealed that
CLCR was a significant predictor of edoxaban clearance
(decreasing renal function decreases renal clearance),
and surgery significantly slowed the rate of edoxaban
absorption [15]. This analysis revealed a direct, linear
relationship between edoxaban exposure and efficacy
but a relationship to bleeding was not identified [15].
The objective of this study was to evaluate the
safety of orally administered edoxaban at a reduced
dose of 15 mg in Japanese patients with SRI (CLCR ≥15
to <30 mL/min) compared with edoxaban 30 mg in
patients with mild renal impairment (MiRI; CLCR ≥50
to ≤80 mL/min) and to subcutaneous fondaparinux
1.5 mg in patients with SRI (CLCR ≥20 to <30 mL/min)
undergoing LLOS. In addition, edoxaban plasma concen-




This was a multicenter, open-label, 3-parallel-group,
phase 3 study in Japanese patients undergoing
LLOS (NCT01857583). Patients with MiRI (CLCR ≥50
to ≤80 mL/min) received oral edoxaban 30 mg once
daily. Among those with SRI, patients with a CLCR ≥20
to <30 mL/min, were randomized to either oral edoxa-
ban 15 mg once daily or subcutaneous fondaparinuxFigure 1 Study design. CLCR = creatinine clearance; HFS = hip fracture su
renal impairment; THA = total hip arthroplasty; TKA = total knee arthroplas1.5 mg once daily; patients with a CLCR ≥15 to <20 mL/min
received edoxaban 15 mg once daily. Fondaparinux was
included as a comparator because it is approved in
Japan for thromboprophylaxis in patients undergoing
LLOS with SRI at a CLCR ≥20 to <30 mL/min. Edoxaban
was administered orally 12 to 24 hours after surgery and
fondaparinux subcutaneously ≥24 hours after surgery.
Both edoxaban and fondaparinux were administered for
11 to 14 days. Follow-up examination was performed at
25 to 35 days after the last dose of study drug (Figure 1).
Concomitant physiotherapy (intermittent pneumatic com-
pression devices or elastic stockings) was permitted
throughout the treatment period.
Patients discontinued treatment if they developed
symptomatic deep vein thrombosis (DVT), pulmonary
embolism (PE), or major bleeding; had evidence of hep-
atic dysfunction; had persistent systolic blood pressure
of >180 mm Hg or diastolic blood pressure of >110 mm Hg;
required anticoagulant drugs, antiplatelet drugs, thrombo-
lytic drugs, or drugs that might affect thrombus forma-
tion; needed postsurgical epidural anesthesia; initiated
hemodialysis; experienced an adverse event (AE) that
was judged sufficient by the investigator for study dis-
continuation; voluntarily requested to withdraw; were
found to be ineligible for continued participation in
the study for any reason; or if the investigator decided
that study participation should be discontinued for any
other reason.
This study was conducted in compliance with the
Declaration of Helsinki, Good Clinical Practice (GCP)
regulations and guidelines, and all applicable local regu-
lations. All study protocols, information for patients,
and informed consent forms received approval from an
institutional review board.
Patient selection
Eligibility criteria included patients who were ≥20 years
of age, had SRI or MiRI, and were undergoing unilateral
TKA or THA (excluding revision surgeries), or HFS for
medial or lateral femoral neck fracture (trochanteric or
subtrochanteric section of the femur) within 10 days ofrgery; MiRI = mild renal impairment; R = randomization; SRI = severe
ty.
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obtained from all patients. Presurgical exclusion criteria
included, but were not limited to, patients undergoing
or possibly undergoing hemodialysis; risk of bleeding;
risk of thromboembolism; and hepatic dysfunction. Post-
surgical exclusion criteria included, but were not limited
to, CLCR <15 mL/min; abnormal bleeding at the site of
spinal anesthesia; abnormal or excessive bleeding during
or immediately after surgery; and the inability to take
oral medication.
Endpoints
At the presurgical evaluation, pretreatment (postsur-
gery), on day 7, on the completion day of treatment, and
during the follow-up examination, the following proce-
dures were performed: blood pressure, pulse rate, blood
sample collection for hematology and blood biochemis-
try tests, and urinalysis. The occurrence of thrombo-
embolic events, bleeding, and all other adverse events
(AEs) were recorded throughout the study.
Safety endpoints included the incidences of any bleed-
ing event (major, clinically relevant non-major [CRNM],
or minor bleeding); major or CRNM bleeding; major
bleeding; CRNM bleeding; minor bleeding; AEs; and
adverse drug reactions (ADRs). Major bleeding was
defined as fatal bleeding; clinically overt bleeding accom-
panied by a decrease in hemoglobin of >2 g/dL or requir-
ing a transfusion of >4 units of blood (1 unit = ~200 mL);
retroperitoneal, intracranial, intraocular, or intrathecal
bleeding; or bleeding requiring repeat surgery. Clinically
relevant non-major bleeding was defined as bleeding
that could not be categorized as major bleeding but
corresponded to a hematoma of ≥5 cm in diameter;
epistaxis or gingival bleeding that occurred in the
absence of external factors and lasted ≥5 min; gastrointes-
tinal bleeding; gross hematuria that persisted for >24 h;
or other bleeding determined by the investigator to be
clinically significant. Minor bleeding was defined as all
other bleeding events that did not fall under the
categories of major or CRNM bleeding. All bleeding
events were reassessed by a bleeding event assessment
committee in a blinded manner. Adverse events were
summarized by system organ class and preferred term
according to the Medical Dictionary for Regulatory
Activities (Version 15.1).
The efficacy endpoint was the incidence of symptom-
atic VTE (composite of symptomatic DVT or PE) during
the treatment period. Venography was not used in this
study because a contrast agent cannot be used in pa-
tients with SRI; therefore, only symptomatic VTE was
assessed. If symptomatic DVT was suspected, it was
confirmed by ultrasonography or computed tomography
(CT) scan. Suspected symptomatic PE was confirmed by
ultrasonography, pulmonary scintigraphy, CT scan, orchest X-ray. All thromboembolic events were assessed
by a thromboembolic event assessor, blinded to treat-
ment group, based on imaging results.
Plasma concentration and biomarker assessments
Blood samples for the determination of plasma edoxaban
concentrations were obtained at predose, 1 to 3 hours
postdose, 4 to 8 hours postdose on day 7, and on the
completion day of study treatment or at the time of
discontinuation. Edoxaban plasma concentrations were
measured using a validated liquid chromatography sep-
aration method with tandem mass detection methods
(Advion BioServices, Inc; Ithaca, NY).
Blood samples for the measurement of biomarkers of
coagulation were obtained at the presurgical examin-
ation, at predose, 1 to 3 hours postdose, 4 to 8 hours
postdose on day 7, and on the completion day of study
treatment or at the time of discontinuation. Biomarkers
assessed were prothrombin time (PT) and activated
partial thromboplastin time (aPTT). Presurgical mea-
sures of PT and aPTT were performed at the study site
(in-hospital) as part of the presurgical examination and
determination of eligibility for enrollment. Biomarker
measurements postsurgery and during the treatment
period were performed at a central laboratory (SRL, Inc;
Hachioji, Japan).
Statistical analysis
All patients who were enrolled, received study drug, had
safety data after the start of study treatment, and had no
significant GCP violations were included in the safety
analysis set. The incidence and corresponding 95% con-
fidence intervals (CIs) of any bleeding, major or CRNM
bleeding, and individual bleeding events (major, CRNM,
and minor) that occurred from the start of study treat-
ment to the day following the end of study treatment
were calculated for each treatment group. For the ana-
lyses of any bleeding and major or CRNM bleeding, the
absolute difference and corresponding 95% CIs were
calculated between patients with SRI who received edox-
aban 15 mg and those with MiRI who received edoxa-
ban 30 mg, as well as between patients with CLCR ≥20
to <30 mL/min who received edoxaban 15 mg and fon-
daparinux 1.5 mg. Additional safety endpoints (AEs,
serious AEs, AEs leading to treatment discontinuation,
and adverse drug reactions [ADRs]) were summarized
according to incidence by treatment group and corre-
sponding 95% CIs.
Data from patients in the safety analysis set with valid
plasma drug concentration data measured at ≥1 time
points were included in descriptive statistics. Descriptive
statistics for edoxaban plasma drug concentrations were
calculated by time point and the severity of renal impair-
ment (SRI and MiRI). In patients with SRI, descriptive
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ing to CLCR level (CLCR ≥15 to <20 mL/min, CLCR ≥ 20
to <30 mL/min).
Data from patients in the safety analysis set with valid
biomarker data measured at ≥1 time points were in-
cluded in descriptive statistics. Descriptive statistics of
measured biomarkers were calculated by treatment
group at each time point. Scatter plots were generated
to determine the relationship between plasma edoxaban
concentrations versus PT and aPTT using individual data
values from day 7 and the completion day of treatment.
The efficacy analysis set included all patients who were
enrolled in the study, received study drug, and had no
significant GCP violations. The incidence of VTE (com-
posite of symptomatic DVT and symptomatic PE), symp-
tomatic DVT, symptomatic PE, VTE-related deaths, and
their respective 95% CIs were calculated by treatment
group.
A total of 80 patients undergoing TKA, THA, or HFS
were to be enrolled, comprising 30 patients with MiRI to
receive edoxaban 30 mg, 30 patients with SRI to receive
edoxaban 15 mg, and 20 patients with SRI to receive
fondaparinux 1.5 mg. The sample size was based on
integrated analyses from previous phase 2 and phase 3
studies of edoxaban in patients undergoing TKA, THA,
or HFS [16-22]. These studies demonstrated that, in
patients with MiRI who were administered edoxaban
30 mg once daily, the incidence of any bleeding and
major or CRNM bleeding was 22.8% and 5.0%, respect-
ively. The proposed sample size of 80 patients provides
95% or higher probability of detection of major or CRNM
bleeding in ≥1 patient assuming that the incidence ofFigure 2 Patient disposition. CLCR = creatinine clearance; EDX = edoxaba
renal impairment. aOne patient randomized to FPX 1.5 mg discontinued pr
surgical wound.major or CRNM bleeding in patients with SRI receiving




A total of 80 patients were enrolled. Of the 50 patients
with SRI, 43 had a CLCR of ≥20 to <30 mL/min and
received either 15 mg edoxaban (n = 22) or 1.5 mg
fondaparinux (n = 21), while 7 patients with a CLCR
of ≥15 to <20 mL/min received edoxaban 15 mg. All
30 patients with MiRI received edoxaban 30 mg once daily
(Figure 2). One patient randomized to the fondaparinux
treatment group received edoxaban 15 mg in error, while a
second patient in the fondaparinux group discontinued
prior to initiation of study treatment. A total of 74 patients
completed the study, as 6 had discontinued study treatment
(1 patient with MiRI and 5 with SRI). Reasons cited for
discontinuation included AE occurrence, voluntary with-
drawal, and ineligibility for continued participation.
Patient demographics and baseline characteristics
The mean age of patients ranged from 78 to 92 years
across the treatment groups. The majority of patients were
female (91%), ≥75 years of age (87%), and weighed ≤60 kg
(86%). The majority of patients in each treatment group
underwent HFS: 58% of patients overall. All patients
received concomitant physiotherapy. Compared with
patients with MiRI, patients with SRI were older (mean
age 78 vs 88 years, respectively) and had a lower mean
body weight (55 vs 43 kg, respectively). A mean body
weight of ≤60 kg was present in 97% of the patientsn; FPX = fondaparinux; MiRI = mild renal impairment; SRI = severe
ior to initiation of study treatment due to excessive bleeding from the
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use of nonsteroidal anti-inflammatory drugs was compar-
able among patients receiving edoxaban or fondaparinux
and use of P-gp inhibitors was low (Table 1).
Bleeding events
The incidence of any bleeding event occurred in 10
(33.3%) patients with MiRI receiving edoxaban 30 mg
compared with 6 (20.7%) patients with SRI receiving edox-
aban 15 mg (absolute difference 12.6% [95% CI: −10.0,
33.6]) and 8 (40.0%) patients with SRI receiving fonda-
parinux. Among patients with CLCR ≥20 to <30 mL/min,
the incidence of any bleeding event trended higher for
those receiving fondaparinux 1.5 mg (40.0%) compared
with those receiving edoxaban 15 mg (22.7%), for an
absolute difference of 17.3% (95% CI, −10.2, 42.1).
Major or CRNM bleeding was reported in 2 (6.7%) pa-
tients with MiRI receiving edoxaban 30 mg, 1 (3.4%)
patient with SRI receiving edoxaban 15 mg, and 1
(5.0%) patient with SRI receiving fondaparinux. All ofTable 1 Patient demographics and baseline characteristics
SRI
Edoxaban 15 mg
CLCR (mL/min) ≥15 to <20
N = 7
Female, n (%) 6 (85.7)
Age, yr
mean (SD) 91.7 (7.1)
<75, n (%) 0
≥75, n (%) 7 (100.0)
Weight, kg
mean (SD) 39.4 (3.8)
≤60, n (%) 7 (100.0)








Physiotherapy use, n (%)
Present 7 (100.0)
Elastic stocking 7 (100.0)
Intermittent pneumatic compression 5 (71.4)
Concomitant use of NSAIDs, n (%) 6 (85.7)
Concomitant use of P-gp inhibitor, n (%) 1 (14.3)
CLCR = creatinine clearance (calculated using the Cockcroft-Gault formula); HFS = hip
anti-inflammatory drugs; P-gp = P-glycoprotein; SRI = severe renal impairment; THAthese were CRNM bleeding events (Table 2). The dif-
ference in rates (95% CI) of major or CRNM bleeding
between patients with MiRI and SRI receiving edoxa-
ban was 3.2% (95% CI, −11.3, 18.1). Among patients
with CLCR ≥20 to <30 mL/min, the incidence of major
or CRNM bleeding in those receiving fondaparinux
1.5 mg was 5.0% compared with 4.5% in patients in the
edoxaban 15-mg group, resulting in an absolute differ-
ence of 0.5% (95% CI, −17.3, 19.4). The single CRNM
bleeding event in the SRI edoxaban group was a
subcutaneous hematoma in a patient with CLCR ≥20
to <30 mL/min. A wound hematoma was reported as
the single CRNM bleeding event in the fondaparinux
treatment group. In the MiRI group, the 2 reported
CRNM bleeding events were hematuria and subcuta-
neous hematoma. Minor bleeding occurred in 10
(33.3%) patients with MiRI receiving edoxaban 30 mg,
5 (17.2%) patients with SRI receiving edoxaban 15 mg,
and 7 (35.0%) patients with SRI receiving fondapari-
nux (Table 2).MiRI
Edoxaban 15 mg Fondaparinux 1.5 mg Edoxaban 30 mg
≥20 to <30 ≥20 to <30 ≥50 to ≤80
N = 22 N = 20 N = 30
19 (86.4) 20 (100.0) 27 (90.0)
86.5 (4.3) 85.7 (8.9) 78.1 (6.5)
0 2 (10.0) 8 (26.7)
22 (100.0) 18 (90.0) 22 (73.3)
44.3 (8.9) 46.1 (8.0) 54.5 (11.1)
21 (95.5) 18 (90.0) 22 (73.3)
1 (4.5) 2 (10.0) 8 (26.7)
27.6 26.2 62.7
20.4–30.0 22.8–30.0 50.7–79.8
5 (22.7) 6 (30.0) 9 (30.0)
1 (4.5) 4 (20.0) 8 (26.7)
16 (72.7) 10 (50.0) 13 (43.3)
22 (100.0) 20 (100.00) 30 (100.0)
21 (95.5) 19 (95.0) 23 (76.7)
8 (36.4) 9 (45.0) 19 (63.3)
20 (90.9) 18 (90.0) 29 (96.7)
0 (0.0) 0 (0.0) 1 (3.3)
fracture surgery; MiRI = mild renal impairment; NSAIDs = nonsteroidal
= total hip arthroplasty; TKA = total knee arthroplasty.
Table 2 Incidence of bleeding events during the treatment perioda
MiRI SRI
Edoxaban 30 mg Edoxaban 15 mg Fondaparinux 1.5 mg
CLCR mL/min ≥50 to ≤80 ≥15 to <30 ≥15 to <20 ≥20 to <30 ≥20 to <30
N 30 29 (total) 7 22 20
Any bleeding events
n (%) 10 (33.3) 6 (20.7) 1 (14.3) 5 (22.7) 8 (40.0)
95% CIb 19.2, 51.2 9.8, 38.4 2.6, 51.3 10.1, 43.4 21.9, 61.3
Major or CRNM bleeding
n (%) 2 (6.7) 1 (3.4) 0 1 (4.5) 1 (5.0)
95% CIb 1.8, 21.3 0.6, 17.2 0.0, 35.4 0.8, 21.8 0.9, 23.6
Major bleeding
n (%) 0 0 0 0 0
95% CIb 0.0, 11.4 0.0, 11.7 0.0, 35.4 0.0, 14.9 0.0, 16.1
CRNM bleeding
n (%) 2 (6.7) 1 (3.4) 0 1 (4.5) 1 (5.0)
95% CIb 1.8, 21.3 0.6, 17.2 0.0, 35.4 0.8, 21.8 0.9, 23.6
Minor bleeding
n (%) 10 (33.3) 5 (17.2) 1 (14.3) 4 (18.2) 7 (35.0)
95% CIb 19.2, 51.2 7.6, 34.5 2.6, 51.3 7.3, 38.5 18.1, 56.7
CI = confidence interval; CRNM = clinically relevant non-major; MiRI = mild renal impairment; SRI = severe renal impairment.
aSafety analysis set; bScore method.
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The incidence of AEs was 73.3% in patients with MiRI
receiving edoxaban 30 mg compared with 62.1% in pa-
tients with SRI receiving edoxaban 15 mg (Table 3).
Among patients with CLCR ≥20 to <30 mL/min, AEs oc-
curred in 12 patients in each group receiving edoxaban
15 mg (54.5%) or fondaparinux 1.5 mg (60.0%). Subcuta-
neous hematoma, blood in the urine, cystitis, and in-
creases in γ-glutamyltransferase were reported more
frequently in the edoxaban groups than in the fondapari-
nux group. In addition, increases in alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), and
blood alkaline phosphatase levels were all reported more
frequently in the SRI edoxaban 15-mg group compared
with the MiRI edoxaban 30-mg group or the SRI fonda-
parinux group. No patients experienced elevations in
ALT or AST levels ≥3× the upper limit of normal (ULN)
or in total bilirubin levels ≥2× ULN.
Two deaths were reported in patients with SRI receiv-
ing edoxaban 15 mg. One patient experienced acute car-
diac failure on the day after the initiation of study
treatment, which resulted in death the same day. The
second death was due to cardiac failure experienced
27 days after the completion of study treatment; the pa-
tient died 2 days later. Both deaths were considered un-
related to the study drug. A total of 8 serious AEs other
than death were reported: 1 occurred in a patient withMiRI receiving edoxaban 30 mg, 4 occurred in 3 patients
with SRI receiving edoxaban 15 mg, and 3 occurred in 3
patients with SRI receiving fondaparinux 1.5 mg. Serious
AEs included dementia, cerebral infarction, pyeloneph-
ritis, and femur fracture in the group with SRI receiving
edoxaban 15 mg. A joint dislocation occurred in a pa-
tient with MiRI receiving edoxaban 30 mg. Sepsis, cere-
bral infarction, and a periprosthetic fracture occurred in
1 patient each with SRI receiving fondaparinux 1.5 mg.
None of the serious AEs were considered related to
study drug.
Three patients discontinued treatment due to an AE. In
the SRI edoxaban 15-mg group (CLCR ≥20 to <30 mL/
min), these included the above-mentioned cardiac failure,
along with a subcutaneous hematoma reported in a sec-
ond patient. The third AE-related discontinuation was a
cerebral infarction, which occurred in a patient with SRI
in the fondaparinux group.
Plasma concentrations
On day 7, plasma concentrations of edoxaban in patients
with SRI receiving a 15-mg dose overlapped considerably
with MiRI patients receiving a 30-mg dose (Figure 3).
Compared with patients with MiRI who received edoxa-
ban 30 mg, the mean (SD) edoxaban plasma concentration
in patients with SRI who received edoxaban 15 mg was
27% higher at predose (31.4 [18.6] vs 24.7 [14.1] ng/mL,
Table 3 Adverse events
MiRI SRI
Edoxaban 30 mg Edoxaban 15 mg Fondaparinux 1.5 mg
CLCR mL/min ≥50 to ≤80 ≥15 to <30 ≥15 to <20 ≥20 to <30 ≥20 to <30
N 30 29 (total) 7 22 20
Adverse events
n (%) 22 (73.3) 18 (62.1) 6 (85.7) 12 (54.5) 12 (60.0)
95% CIa 55.6, 85.8 44.0, 77.3 48.7, 97.4 34.7, 73.1 38.7, 78.1
MedDRA preferred term, reported by ≥2 patients, n (%)
Alanine aminotransferase increased 2 (6.7) 3 (10.3) 1 (14.3) 2 (9.1) 0 (0.0)
Aspartate aminotransferase increased 1 (3.3) 5 (17.2) 2 (28.6) 3 (13.6) 0 (0.0)
Blood alkaline phosphatase increased 0 (0.0) 6 (20.7) 1 (14.3) 5 (22.7) 0 (0.0)
Blood bilirubin increased 2 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Blood lactate dehydrogenase increased 0 (0.0) 2 (6.9) 1 (14.3) 1 (4.5) 0 (0.0)
Blood urine present 4 (13.3) 2 (6.9) 0 (0.0) 2 (9.1) 1 (5.0)
Cystitis 2 (6.7) 5 (17.2) 2 (28.6) 3 (13.6) 1 (5.0)
Gamma-glutamyltransferase increased 5 (16.7) 6 (20.7) 2 (28.6) 4 (18.2) 0 (0.0)
Hemorrhage subcutaneous 6 (20.0) 1 (3.4) 0 (0.0) 1 (4.5) 3 (15.0)
Hemoglobin decreased 0 (0.0) 1 (3.4) 1 (14.3) 0 (0.0) 3 (15.0)
Nasopharyngitis 0 (0.0) 2 (6.9) 0 (0.0) 2 (9.1) 1 (5.0)
Red blood cells urine positive 2 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Subcutaneous hematoma 1 (3.3) 3 (10.3) 1 (14.3) 2 (9.1) 0 (0.0)
Urinary tract infection 2 (6.7) 1 (3.4) 0 (0.0) 1 (4.5) 2 (10.0)
Adverse drug reactions
n (%) 13 (43.3) 7 (24.1) 1 (14.3) 6 (27.3) 6 (30.0)
95% CIa 27.4, 60.8 12.2, 42.1 2.6, 51.3 13.2, 48.2 14.5, 51.9
Serious adverse events
n (%) 1 (3.3) 5 (17.2) 3 (42.9) 2 (9.1) 3 (15.0)
95% CIa 0.6, 16.7 7.6, 34.5 15.8, 75.0 2.5, 27.8 5.2, 36.0
Adverse events leading to treatment discontinuation
n (%) 0 2 (6.9) 0 2 (9.1) 1 (5.0)
95% CIa 0.0, 11.4 1.9, 22.0 0.0, 35.4 2.5, 27.8 0.9, 23.6
CI = confidence interval; CLCR = creatinine clearance; MedDRA =medical dictionary for regulatory activities; MiRI = mild renal impairment; SRI = severe
renal impairment.
aScore method.
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(106 [75.8] vs 140 [120] ng/mL, respectively); and
37% lower at 4 to 8 hours postdose (113 [24.9] vs 179
[132] ng/mL). Within the SRI edoxaban 15-mg group,
those with CLCR ≥15 to <20 mL/min had a 2-fold higher
mean edoxaban plasma concentration compared to those
with CLCR ≥20 to <30 mL/min at predose on day 7 (50.7
[18.1] vs 24.6 [13.6]); however, mean concentrations were
comparable at 1 to 3 hours postdose (106 [72.9] vs 106
[78.7], respectively) and 4 to 8 hours postdose (126 [18.7]
vs 109 [25.8], respectively). Edoxaban plasma concentra-
tions on the completion day of study treatment were simi-
lar to those on day 7.Biomarkers
PT
On day 7, mean PT in SRI patients receiving edoxaban
15 mg was comparable to that of MiRI patients receiving
edoxaban 30 mg at predose (14.0 vs 13.7 seconds, re-
spectively), 1 to 3 hours postdose (16.1 vs 16.8 seconds,
respectively) and 4 to 8 hours postdose (16.2 vs 17.4 -
seconds, respectively). For SRI patients receiving fonda-
parinux 1.5 mg, mean PT was 13.5 seconds at predose
and there was no marked prolongation of mean PT at 1
to 3 hours (13.6 seconds) or 4 to 8 hours (13.5 seconds)
postdose. A similar time course of mean PT was ob-
served on the completion day of study treatment to that
Figure 3 Mean plasma concentrations of edoxaban on day 7. Horizontal line =median; + =mean; error bars =minimum and maximum
values within 1.5 interquartile range; • = outliers; SRI = severe renal impairment; MiRI = mild renal impairment.
Table 4 Mean PT and aPTT values by treatment group on day 7 and at treatment completion
Day 7 Completion day of treatment
Parameter Treatment group Pre dose 1 to 3 h 4 to 8 h Pre dose 1 to 3 h 4 to 8 h
PT (s) MiRI n Edoxaban 30 mg 29 29 29 30 29 28
Mean (SD) CLCR ≥50 to <80 mL/min 13.7 (1.1) 16.8 (3.6) 17.4 (1.8) 13.6 (1.0) 17.6 (3.4) 17.5 (2.1)
SRI n Edoxaban 15 mg (total) 27 27 27 26 25 26
Mean (SD) CLCR ≥15 to <30 mL/min 14.0 (1.2) 16.1 (2.1) 16.2 (1.4) 14.1 (1.1) 15.9 (1.9) 16.5 (1.6)
Edoxaban 15 mg 7 7 7 6 7 7
CLCR ≥15 to <20 mL/min 14.8 (1.3) 16.9 (2.1) 16.9 (1.1) 15.0 (1.5) 16.6 (2.3) 17.1 (2.5)
Edoxaban 15 mg 20 20 20 20 18 19
CLCR ≥20 to <30 mL/min 13.8 (1.0) 15.8 (2.1) 15.9 (1.4) 13.9 (0.9) 15.6 (1.8) 16.3 (1.2)
Fondaparinux 20 20 20 19 17 18
CLCR ≥20 to <30 mL/min 13.5 (0.9) 13.6 (0.9) 13.5 (0.9) 13.7 (1.1) 13.7 (1.1) 13.6 (1.1)
aPTT (s) MiRI n Edoxaban 30 mg 29 29 29 30 29 28
Mean (SD) CLCR ≥50 to <80 mL/min 32.2 (3.3) 37.7 (6.2) 38.9 (6.3) 31.7 (3.6) 39.3 (7.5) 39.8 (6.5)
SRI n Edoxaban 15 mg (total) 27 27 27 26 25 26
Mean (SD) CLCR ≥15 to <30 mL/min 31.6 (3.5) 35.7 (6.0) 36.1 (4.2) 31.0 (4.3) 34.0 (4.8) 35.6 (4.8)
Edoxaban 15 mg 7 7 7 6 7 7
CLCR ≥15 to <20 mL/min 32.7 (4.4) 36.6 (7.3) 36.2 (7.0) 31.1 (4.9) 34.2 (6.0) 34.7 (7.0)
Edoxaban 15 mg 20 20 20 20 18 19
CLCR ≥20 to <30 mL/min 31.2 (3.1) 35.4 (5.7) 36.1 (3.0) 31.0 (4.2) 34.0 (4.4) 36.0 (3.8)
Fondaparinux 20 20 20 19 17 18
CLCR ≥20 to <30 mL/min 32.5 (4.4) 32.6 (4.5) 32.3 (5.0) 32.9 (3.9) 33.2 (5.8) 33.5 (4.7)
aPTT = activated partial thromboplastin time; CLCR = creatinine clearance; MiRI =mild renal impairment; PT = prothrombin time; SD = standard deviation; SRI = severe
renal impairment.
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Fuji et al. Thrombosis Journal  (2015) 13:6 Page 9 of 11of day 7 in all treatment groups (Table 4). The relation-
ship between PT and plasma edoxaban concentration in
patients with SRI receiving edoxaban 15 mg was similar
to that in patients with MiRI receiving edoxaban 30 mg
(Figure 4A). Mean PT was prolonged as plasma edoxa-
ban concentration increased on both day 7 and at the
completion of study treatment.
aPTT
The time course of mean aPTT observed on day 7 and
on the completion day of treatment was also similar to
those seen for mean PT in all treatment groups (Table 4).
Mean aPTT was prolonged at 1 to 3 hours and 4 to
8 hours postdose on day 7 in all edoxaban treatment
groups, while no prolongation was seen in the fondapar-
inux treatment group. A similar time course of mean
aPTT was observed on the completion day of study
treatment compared with that of day 7 in all treatmentFigure 4 Relationship between plasma edoxaban concentrations a
partial thromboplastin time; CLCR = creatinine clearance; EDX = edoxaban; MiR
impairment.groups (Table 4). The relationship between aPTT and
plasma edoxaban concentration in patients with SRI
receiving edoxaban 15 mg was also similar to that in
patients with MiRI receiving edoxaban 30 mg. On both
day 7 and the completion day of treatment, aPTT was
prolonged as plasma edoxaban concentration increased
(Figure 4B).
Thromboembolic events
No thromboembolic events occurred in any treatment
group during the duration of the study.
Discussion
This study evaluated the safety and relationship between
plasma concentration and coagulation biomarkers fol-
lowing edoxaban 15 mg once daily dosing in patients
with SRI undergoing TKA, THA, or HFS. The incidence
of bleeding events were similar between patients withnd A) PT; B) aPTT on day 7 and completion. aPTT = activated
I =mild renal impairment; PT = prothrombin time; SRI = severe renal
Fuji et al. Thrombosis Journal  (2015) 13:6 Page 10 of 11SRI who received edoxaban 15 mg once daily compared
with patients with MiRI who received edoxaban 30 mg
once daily. Likewise, among patients with SRI who re-
ceived either edoxaban 15 mg or fondaparinux 1.5 mg
once daily, major or CRNM bleeding rates were similar.
Of interest, no major bleeding events occurred during
this study in any treatment group. Minor bleeding rates
appeared to be lower in the SRI edoxaban 15-mg group
compared with both the MiRI edoxaban 30-mg and SRI
fondaparinux groups. Edoxaban plasma concentrations
did differ between the groups from 24% to 37% at differ-
ent timepoints, but no notable differences on mean PT
and aPTT levels were observed.
Overall, bleeding rates observed in the current study
are similar to those reported in phase 3 studies that eval-
uated the safety and efficacy of edoxaban 30 mg once
daily for the prevention of VTE in Japanese patients
undergoing THA, TKA, or HFS [20-22]. For example, in
the current study, the incidence of major or CRNM
bleeding was 6.7% in the MiRI edoxaban 30-mg group
and 3.4% in the SRI edoxaban 15-mg group. In the phase
3 THA [20], TKA [22], and HFS [21] studies, these rates
were 2.6%, 6.2%, and 3.4%, respectively. Patients with
SRI were excluded from these studies.
The clinical results of the current study are supported
by edoxaban plasma concentration and coagulation bio-
marker results. While mean edoxaban plasma concentra-
tions differed between patients in the SRI 15-mg group
and the MiRI 30-mg group at each time point on day 7,
the range of individual measures overlapped consider-
ably, suggesting similar exposure. In addition, edoxaban-
induced prolongation of PT and aPTT were similar
between the two edoxaban treatment groups. The ob-
served prolongation of PT and aPTT correlated with in-
dividual edoxaban plasma concentrations; as the plasma
concentrations increased, PT and aPTT were prolonged
and this concentration/biomarker relationship was not
affected by the severity of renal impairment. These rela-
tionships were consistent with previously documented
data from healthy volunteers [13] and patients undergo-
ing THA [20] or HFS [21].
There were no reports of thromboembolic events dur-
ing this study. All patients enrolled utilized physiother-
apy, which may have increased the thromboprophylactic
potential of treatment. The combination of pharma-
cologic and mechanical thromboembolic prophylaxis
has been shown to further reduce the occurrence of
thromboembolic events versus compression or pharma-
cologic prophylaxis alone [23], and this combination
therapy is recommended by the Japanese Circulation So-
ciety for patients at the highest risk for developing
thromboembolisms [4].
Serious AEs occurred in 16% of patients with SRI,
compared with 3% of those with MiRI. This is notunexpected, as patients with decreasing renal function
have increasing comorbidity burdens [24,25]. Further-
more, none of the serious AEs reported in this study
were considered related to study drug.
A potential limitation of this study is the small number
of patients enrolled, which does not provide enough
power to determine any statistically significant differences
in the rate of bleeding events between treatment groups
or to evaluate efficacy. However, the objective of this study
was to evaluate the safety of the edoxaban 15 mg once
daily dose in patients with SRI undergoing LLOS, not to
compare treatments. The data presented here suggest that
edoxaban 15 mg once daily is well tolerated in this patient
population, but larger studies would be needed to confirm
these results and provide data regarding efficacy.
Conclusions
The pharmacologic options available in Japan for the
prevention of VTE in patients with SRI undergoing
LLOS are limited. As previously mentioned, earlier
phase 3 studies leading to the approval of edoxaban
30 mg for the prevention of thromboembolic events
excluded patients with SRI and thus edoxaban is not
presently approved for use in that patient population.
The results presented here suggest that edoxaban 15 mg
does not increase the risk for bleeding in Japanese
patients with SRI undergoing LLOS and may be an
option for thromboprophylaxis, however this requires
confirmation in a larger study.
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